## Cosmo Godino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7812328/publications.pdf

Version: 2024-02-01

145 papers 4,532 citations

38 h-index 62 g-index

148 all docs

148
docs citations

times ranked

148

4586 citing authors

#	Article	IF	CITATIONS
1	Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment. Circulation, 2007, 116, 745-754.	1.6	430
2	Long-Term Outcome of Percutaneous Coronary Intervention for Chronic Total Occlusions. JACC: Cardiovascular Interventions, 2011, 4, 952-961.	2.9	260
3	Incidence, Predictors, Management, Immediate and Long-Term Outcomes Following Grade III Coronary Perforation. JACC: Cardiovascular Interventions, 2011, 4, 87-95.	2.9	170
4	5-Year Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation Versus Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Lesions. JACC: Cardiovascular Interventions, 2010, 3, 595-601.	2.9	136
5	Predictors of moderateâ€toâ€severe paravalvular aortic regurgitation immediately after corevalve implantation and the impact of postdilatation. Catheterization and Cardiovascular Interventions, 2011, 78, 432-443.	1.7	125
6	Outcomes After Transcatheter Aortic Valve Implantation With Both Edwards-SAPIEN and CoreValve Devices in a Single Center. JACC: Cardiovascular Interventions, 2010, 3, 1110-1121.	2.9	124
7	A new technique for vascular access management in transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2010, 75, 784-793.	1.7	123
8	Subintimal tracking and reâ€entry technique with contrast guidanc: A safer approach. Catheterization and Cardiovascular Interventions, 2008, 72, 790-796.	1.7	105
9	Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet, The, 2020, 395, 1487-1495.	13.7	104
10	Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Stent Implantation in Patients Taking Chronic Oral Anticoagulation. JACC: Cardiovascular Interventions, 2008, 1, 56-61.	2.9	85
11	The role of sex on VARC outcomes following transcatheter aortic valve implantation with both Edwards SAPIENâ, $\phi$ and Medtronic CoreValve ReValving System® devices: the Milan registry. EuroIntervention, 2011, 7, 556-563.	3.2	80
12	Rotational atherectomy followed by drug-eluting stent implantation in calcified coronary lesions. EuroIntervention, 2009, 5, 370-374.	3.2	78
13	Outcome after percutaneous edge-to-edge mitral repair for functional and degenerative mitral regurgitation: a systematic review and meta-analysis. Heart, 2018, 104, 306-312.	2.9	77
14	MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. Journal of Heart and Lung Transplantation, 2020, 39, 1353-1362.	0.6	75
15	Predictors of cardiac death in patients with coronary chronic total occlusion not revascularized by PCI. International Journal of Cardiology, 2013, 168, 1402-1409.	1.7	73
16	Heyde's Syndrome Incidence and Outcome in Patients Undergoing Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2013, 61, 687-689.	2.8	73
17	Coronary chronic total occlusions. Catheterization and Cardiovascular Interventions, 2012, 79, 20-27.	1.7	71
18	Long-Term Outcomes After the Percutaneous Treatment of Drug-Eluting Stent Restenosis. JACC: Cardiovascular Interventions, 2011, 4, 155-164.	2.9	66

#	Article	IF	CITATIONS
19	Silent cerebral injury after transcatheter aortic valve implantation and the preventive role of embolic protection devices: A systematic review and meta-analysis. International Journal of Cardiology, 2016, 221, 97-106.	1.7	66
20	Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence International Journal of Cardiology, 2021, 324, 261-266.	1.7	65
21	Periprocedural and Short-Term Outcomes of Transfemoral Transcatheter Aortic Valve Implantation With the Sapien XT as Compared With the Edwards Sapien Valve. JACC: Cardiovascular Interventions, 2011, 4, 743-750.	2.9	62
22	Patterns of restenosis after drug-eluting stent implantation: insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents. European Heart Journal, 2006, 27, 2330-2337.	2.2	59
23	Long-Term Follow-Up on a Large Cohort of "Full-Metal Jacket―Percutaneous Coronary Intervention Procedures. Circulation: Cardiovascular Interventions, 2009, 2, 416-422.	3.9	54
24	An Intense and Short-Lasting Burst of Neutrophil Activation Differentiates Early Acute Myocardial Infarction from Systemic Inflammatory Syndromes. PLoS ONE, 2012, 7, e39484.	2.5	52
25	CTO recanalization by intraocclusion injection of contrast: The microchannel technique. Catheterization and Cardiovascular Interventions, 2008, 71, 20-26.	1.7	49
26	Italian Society of Interventional Cardiology ( <scp>Glse</scp> ) registry Of Transcatheter treatment of mitral valve r <scp>egurgitaTiOn</scp> ( <scp>GIOTTO</scp> ): impact of valve disease aetiology and residual mitral regurgitation after <scp>MitraClip</scp> implantation. European Journal of Heart Failure, 2021, 23, 1364-1376.	7.1	49
27	Left ventricular reverse remodelling predicts longâ€term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry. European Journal of Heart Failure, 2019, 21, 196-204.	7.1	47
28	Impact of target vessel on longâ€term survival after percutaneous coronary intervention for chronic total occlusions. Catheterization and Cardiovascular Interventions, 2013, 82, 76-82.	1.7	46
29	Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes. JAMA Cardiology, 2018, 3, 234.	6.1	46
30	Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy?. Thrombosis Journal, 2009, 7, 4.	2.1	45
31	Clinical and Angiographic Outcomes After Percutaneous Recanalization of Chronic Total Saphenous Vein Graft Occlusion Using Modern Techniques. American Journal of Cardiology, 2010, 106, 1721-1727.	1.6	45
32	Right ventricular evaluation to improve survival outcome in patients with severe functional mitral regurgitation and advanced heart failure undergoing MitraClip therapy. International Journal of Cardiology, 2016, 223, 574-580.	1.7	45
33	Crossing CTOsâ€"The tips, tricks, and specialist Kit that can mean the difference between success and failure. Catheterization and Cardiovascular Interventions, 2009, 74, 1019-1046.	1.7	44
34	Trans-apical and trans-axillary percutaneous aortic valve implantation as alternatives to the femoral route: short- and middle-term results. European Journal of Cardio-thoracic Surgery, 2011, 40, 49-55.	1.4	44
35	A Score to Assess Mortality After Percutaneous Mitral Valve Repair. Journal of the American College of Cardiology, 2022, 79, 562-573.	2.8	44
36	Transcatheter valve-in-valve implantation with the Edwards SAPIEN in patients with bioprosthetic heart valve failure: the Milan experience. EuroIntervention, 2012, 7, 1275-1284.	3.2	43

#	Article	IF	Citations
37	Two-year cardiac mortality after MitraClip treatment of functional mitral regurgitation in ischemic and non-ischemic dilated cardiomyopathy. International Journal of Cardiology, 2018, 269, 33-39.	1.7	42
38	Long-Term Clinical Outcomes of Percutaneous Coronary Intervention for Chronic Total Occlusions in Patients With Versus Without Diabetes Mellitus. American Journal of Cardiology, 2011, 108, 924-931.	1.6	41
39	Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2011, 4, 387-395.	3.9	41
40	Predictors of restenosis after treatment of bifurcational lesions with paclitaxel eluting stents: A multicenter prospective registry of 150 consecutive patients. Catheterization and Cardiovascular Interventions, 2007, 69, 416-424.	1.7	38
41	Clinical and Angiographic Follow-Up of Small Vessel Lesions Treated With Paclitaxel-Eluting Stents (from the TRUE Registry). American Journal of Cardiology, 2008, 102, 1002-1008.	1.6	33
42	Predictors of restenosis following contemporary subintimal tracking and reentry technique: The importance of final <scp>TIMI</scp> flow grade. Catheterization and Cardiovascular Interventions, 2016, 87, 884-892.	1.7	32
43	Safety and Efficacy of Polymer-Free Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2019, 12, e007311.	3.9	30
44	Clinical and Procedural Predictors of Suboptimal Outcome After the Treatment of Drug-Eluting Stent Restenosis in the Unprotected Distal Left Main Stem. Circulation: Cardiovascular Interventions, 2012, 5, 491-498.	3.9	29
45	Clinical Outcomes After Unrestricted Implantation of Everolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2009, 2, 1219-1226.	2.9	28
46	Beneficial Electrophysiological Effects of Trimetazidine in Patients With Postischemic Chronic Heart Failure. Journal of Cardiovascular Pharmacology and Therapeutics, 2010, 15, 24-30.	2.0	28
47	Retrograde popliteal access as bailâ€out strategy for challenging occlusions of the superficial femoral artery: A multicenter registry. Catheterization and Cardiovascular Interventions, 2012, 79, 1188-1193.	1.7	27
48	Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: A proposed alternative regimen. International Journal of Cardiology, 2013, 165, 444-447.	1.7	27
49	Frequency of Slow Coronary Flow Following Successful Stent Implantation and Effect of Nitroprusside. American Journal of Cardiology, 2007, 99, 916-920.	1.6	26
50	Impact and evolution of right ventricular dysfunction after successful MitraClip implantation in patients with functional mitral regurgitation. IJC Heart and Vasculature, 2016, 11, 90-98.	1.1	26
51	Sirolimus-eluting and paclitaxel-eluting stents for the treatment of coronary bifurcations. American Heart Journal, 2008, 156, 745-750.	2.7	25
52	Expansion of T-Cell Receptor ζ <sup>dim</sup> Effector T Cells in Acute Coronary Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 2305-2311.	2.4	25
53	One-year clinical outcome of amphilimus polymer-free drug-eluting stent in diabetes mellitus patients. International Journal of Cardiology, 2016, 214, 113-120.	1.7	25
54	Percutaneous left atrial appendage closure versus non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation and high bleeding risk. EuroIntervention, 2020, 15, 1548-1554.	3.2	25

#	Article	IF	CITATIONS
55	Impact of Residual Chronic Total Occlusion of Right Coronary Artery on the Long-term Outcome in Patients Treated for Unprotected Left Main Disease. Circulation: Cardiovascular Interventions, 2013, 6, 154-160.	3.9	24
56	Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease. Internal and Emergency Medicine, 2019, 14, 1259-1270.	2.0	24
57	Incidence of Bleeding and Compliance on Prolonged Dual Antiplatelet Therapy (Aspirin +) Tj ETQq1 1 0.784314	4 rgBT /Ove 1.6	rlock 10 Tf 50 23
58	Real-World Safety and Efficacy of Transcatheter Mitral Valve Repair With MitraClip: Thirty-Day Results From the Italian Society of Interventional Cardiology (Glse) Registry Of Transcatheter Treatment of Mitral Valve RegurgitaTiOn (GIOTTO). Cardiovascular Revascularization Medicine, 2020, 21, 1057-1062.	0.8	23
59	The Long-Term Clinical Outcome of T-Stenting and Small Protrusion Technique for Coronary Bifurcation Lesions. JACC: Cardiovascular Interventions, 2013, 6, 554-561.	2.9	22
60	Incidence of Overall Bleeding in Patients Treated With Intra-Aortic Balloon Pump During Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 350-357.	2.9	21
61	Quality of life improvement is maintained up to two years after transcatheter aortic valve implantation in high-risk surgical candidates. EuroIntervention, 2012, 8, 429-436.	3.2	21
62	Transcatheter Edge-to-Edge Repair in COAPT-Ineligible Patients: Incidence and Predictors of 2-Year Good Outcome. Canadian Journal of Cardiology, 2022, 38, 320-329.	1.7	20
63	Comparison of Long-Term Clinical and Angiographic Outcomes Following Implantation of Bare Metal Stents and Drug-Eluting Stents in Aorto-Ostial Lesions. American Journal of Cardiology, 2011, 108, 1055-1060.	1.6	19
64	Risk of cardiac and sudden death with and without revascularisation of a coronary chronic total occlusion. Heart, 2019, 105, 1096-1102.	2.9	19
65	Transseptal access for MitraClipÂ $^{\circ}$ procedures using surgical diathermy under echocardiographic guidance. EuroIntervention, 2012, 8, 579-586.	3.2	19
66	Do Patients Undergoing MitraClip Implantation Require Routine ICU Admission?. Journal of Cardiothoracic and Vascular Anesthesia, 2014, 28, 1479-1483.	1.3	18
67	The impact of main branch restenosis on long term mortality following drugâ€eluting stent implantation in patients with ⟨i⟩de novo⟨l⟩ unprotected distal left main bifurcation coronary lesions: The Milan and Newâ€Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2014. 84. 341-348.	1.7	18
68	Estimating incidence of organ cancer related to PCI radiation exposure in patients treated for acute and chronic total occlusions. Journal of Invasive Cardiology, 2013, 25, 441-5.	0.4	18
69	Coronary Left Main and Nonâ€Left Main Bifurcation Angles: How are the Angles Modified by Different Bifurcation Stenting Techniques?. Journal of Interventional Cardiology, 2010, 23, 382-393.	1.2	17
70	Comparison of the Long-Term Safety and Efficacy of Drug-Eluting and Bare-Metal Stent Implantation in Saphenous Vein Grafts. Circulation: Cardiovascular Interventions, 2010, 3, 249-256.	3.9	17
71	Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study. International Journal of Cardiology, 2021, 344, 240-245.	1.7	17
72	Polymer-free amphilimus-eluting stent versus biodegradable polymer biolimus-eluting stent in patients with and without diabetes mellitus. International Journal of Cardiology, 2017, 245, 69-76.	1.7	16

#	Article	IF	Citations
73	Use of <scp>edgeâ€toâ€edge</scp> percutaneous mitral valve repair for severe mitral regurgitation in cardiogenic shock: A multicenter observational experience ( <scp>MITRAâ€5HOCK</scp> study). Catheterization and Cardiovascular Interventions, 2021, 98, E163-E170.	1.7	16
74	Treatment of iatrogenic occlusive coronary dissections: a novel approach. EuroIntervention, 2011, 7, 106-111.	3.2	16
75	One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in all-comers population. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry). International Journal of Cardiology, 2018, 260, 36-41.	1.7	15
76	Inappropriate dose of nonvitamin-K antagonist oral anticoagulants: prevalence and impact on clinical outcome in patients with nonvalvular atrial fibrillation. Journal of Cardiovascular Medicine, 2020, 21, 751-758.	1.5	15
77	Differences in the Clinical and Angiographic Characteristics of Chronic Total Occlusion Lesions in the Three Major Coronary Arteries. Journal of Interventional Cardiology, 2014, 27, 44-49.	1.2	14
78	Long-term follow-up (four years) of unprotected left main coronary artery disease treated with paclitaxel-eluting stents (from the TRUE Registry). EuroIntervention, 2010, 5, 906-916.	3.2	14
79	Mitral valve surgery after a failed MitraClip procedure. Interactive Cardiovascular and Thoracic Surgery, 2021, 32, 380-385.	1.1	14
80	First-in-Man MitraClip Implantation to Treat Late Postoperative Systolic Anterior Motion. Circulation: Cardiovascular Interventions, 2014, 7, 860-862.	3.9	13
81	Clinical outcomes of realâ€world patients treated with an amphilimus polymerâ€free stent versus new generation everolimusâ€eluting stents. Catheterization and Cardiovascular Interventions, 2015, 86, 1168-1176.	1.7	13
82	Clinical trial experience with the MitraClip catheter based mitral valve repair system. International Journal of Cardiovascular Imaging, 2011, 27, 1155-1164.	1.5	12
83	Analysis of a Low Dose Protocol to Reduce Patient Radiation Exposure During Percutaneous Coronary Interventions. American Journal of Cardiology, 2017, 119, 203-209.	1.6	12
84	Midterm and one-year outcome of amphilimus polymer free drug eluting stent in patients needing short dual antiplatelet therapy. Insight from the ASTUTE registry (AmphilimuS iTalian mUlticenTer) Tj ETQq0 0 C	) rgBIT7/Ove	erlo <b>ak</b> 10 Tf 50
85	Relationship between Syntax Score and prognostic localization of coronary artery lesions with conventional risk factors, plasma profile markers, and carotid atherosclerosis (CAPP Study 2). International Journal of Cardiology, 2018, 257, 306-311.	1.7	11
86	Predictors of optimal procedural result after transcatheter edgeâ€toâ€edge mitral valve repair in secondary mitral regurgitation. Catheterization and Cardiovascular Interventions, 2022, 99, 1626-1635.	1.7	11
87	Long-term follow-up of multivessel percutaneous coronary intervention with drug-eluting stents for de novo lesions with correlation to the SYNTAX score. Cardiovascular Revascularization Medicine, 2011, 12, 220-227.	0.8	10
88	Resultados a muy largo plazo tras la implantación de stents liberadores de fármacos en la estenosis de arteria coronaria principal izquierda no protegida: experiencia de un centro. Revista Espanola De Cardiologia, 2013, 66, 24-33.	1.2	10
89	Prognostic role of stress/rest myocardial perfusion scintigraphy in patients with cardiac syndrome x. International Journal of Cardiology, 2014, 173, 467-471.	1.7	10
90	PFO closure with only fluoroscopic guidance: 7 years realâ€world single centre experience. Catheterization and Cardiovascular Interventions, 2015, 86, 105-112.	1.7	10

#	Article	IF	Citations
91	Clinical Outcomes Following Protected Carotid Artery Stenting in Symptomatic and Asymptomatic Patients. Journal of Endovascular Therapy, 2010, 17, 298-307.	1.5	9
92	Aortic Valvuloplasty as Bridging for TAVI in High-Risk Patients with Heyde's Syndrome: A Case Report. Case Reports in Medicine, 2012, 2012, 1-3.	0.7	9
93	Resolute italian study in all comers. Catheterization and Cardiovascular Interventions, 2012, 79, 567-574.	1.7	9
94	Discrepancies in vessel sizing between angiography and intravascular ultrasound varies according to the vessel evaluated. International Journal of Cardiology, 2013, 168, 3791-3796.	1.7	9
95	Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: The <scp>STATIPLAT</scp> randomized study. Clinical Cardiology, 2017, 40, 605-611.	1.8	9
96	Drug-eluting stent implantation in coronary trifurcation lesions. Journal of Invasive Cardiology, 2007, 19, 157-62.	0.4	9
97	Emerging Approaches of Transcatheter Valve Repair/Insertion. Cardiology Research and Practice, 2010, 2010, 1-11.	1.1	8
98	Comparison of abluminal biodegradable polymer biolimusâ€eluting stents and durable polymer everolimusâ€eluting stents in the treatment of coronary bifurcations. Catheterization and Cardiovascular Interventions, 2014, 83, 889-895.	1.7	8
99	One-year outcome of biolimus eluting stent with biodegradable polymer in all comers: The Italian Nobori Stent Prospective Registry. International Journal of Cardiology, 2014, 177, 11-16.	1.7	8
100	Prognostic Value of Pre-operative Atrial Fibrillation in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation. American Journal of Cardiology, 2021, 143, 51-59.	1.6	8
101	Multifocal, Persistent Cardiac Uptake of [18-F]-Fluoro-Deoxy-Glucose Detected by Positron Emission Tomography in Patients With Acute Myocardial Infarction. Circulation Journal, 2008, 72, 1821-1828.	1.6	7
102	Outcomes of a novel thin-strut bioresorbable-polymer sirolimus-eluting stent in patients with chronic total occlusions: A multicenter registry. International Journal of Cardiology, 2018, 258, 36-41.	1.7	7
103	Left atrial appendage closure: a new strategy for cardioembolic events despite oral anticoagulation. Panminerva Medica, 2021, , .	0.8	7
104	Young Patient with Advanced Heart Failure No Longer a Candidate for Heart Transplantation after MitraClipÃ,® Procedure. Journal of Heart Valve Disease, 2017, 26, 234-236.	0.5	7
105	Prolonged Double Antiplatelet Therapy in a Cohort of "De Novo―Diabetic Patients Treated With Drug-Eluting Stent Implantation. American Journal of Cardiology, 2010, 105, 1395-1401.	1.6	6
106	Association of LOXIN, a new functional splicing isoform of the OLR1 gene, with severity and prognostic localization of critical coronary artery stenoses. Journal of Cardiovascular Medicine, 2014, 15, 391-396.	1.5	6
107	Drug-eluting stent use after coronary atherectomy. Journal of Cardiovascular Medicine, 2016, 17, 665-672.	1.5	6
108	Observed versus predicted mortality after MitraClip treatment in patients with symptomatic heart failure and significant functional mitral regurgitation. European Journal of Heart Failure, 2018, 20, 1495-1496.	7.1	6

#	Article	IF	CITATIONS
109	Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and extreme body weight. European Journal of Clinical Investigation, 2022, 52, e13658.	3.4	6
110	Long-term clinical outcomes of patients with rheumatoid arthritis and concomitant coronary artery disease. American Journal of Cardiovascular Disease, 2017, 7, 9-18.	0.5	6
111	Oneâ€year clinical outcome of biodegradable polymer sirolimusâ€eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry. Catheterization and Cardiovascular Interventions, 2019, 94, 972-979.	1.7	5
112	One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients needing short dual antiplatelet therapy. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS) Tj ETQq0 0	0 ngBT /O	verslock 10 Tf
113	Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation. American Journal of Cardiology, 2020, 129, 122-124.	1.6	5
114	MitraClip Treatment of Secondary Mitral Regurgitation in Heart Failure with Reduced Ejection Fraction: Lessons and Implications from Trials and Registries. Structural Heart, 2020, 4, 247-253.	0.6	5
115	Edgeâ€toâ€edge percutaneous mitral repair for functional ischaemic and nonâ€ischaemic mitral regurgitation: a systematic review and metaâ€analysis. ESC Heart Failure, 2022, 9, 3177-3187.	3.1	5
116	Management of large coronary dissection after STAR. Cardiovascular Revascularization Medicine, 2014, 15, 58-60.	0.8	4
117	Reducer, extracorporeal shockwave therapy or stem cells in refractory angina. Journal of Cardiovascular Medicine, 2018, 19, 42-44.	1.5	4
118	Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure. Journal of Cardiovascular Medicine, 2018, 19, 351-356.	1.5	4
119	Oneâ€year clinical outcome of biodegradable polymer sirolimusâ€eluting stent in diabetic patients: Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry). Catheterization and Cardiovascular Interventions, 2020, 96, 255-265.	1.7	4
120	How should I treat a long and huge coronary pseudoaneurysm after spontaneous coronary artery dissection?. EuroIntervention, 2011, 6, 1131-1136.	3.2	4
121	Safety and efficacy of direct oral anticoagulants (DOACs) in very elderly patients (≥85 years old) with non-valvular atrial fibrillation. Minerva Medica, 2023, 114, .	0.9	4
122	Percutaneous Coronary Intervention in Patients With a Single Remaining Vessel. American Journal of Cardiology, 2007, 99, 470-471.	1.6	3
123	Very Long-term Outcomes Following Drug-eluting Stent Implantation for Unprotected Left Main Coronary Artery Stenosis: A Single Center Experience. Revista Espanola De Cardiologia (English Ed ), 2013, 66, 24-33.	0.6	3
124	Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention. Clinical Drug Investigation, 2017, 37, 105-120.	2.2	3
125	Effect of Chronic Kidney Disease on 5-Year Outcome in Patients With Heart Failure and Secondary Mitral Regurgitation Undergoing Percutaneous MitraClip Insertion. American Journal of Cardiology, 2022, 171, 105-114.	1.6	3
126	Long-Term Preservation of Left Ventricular Systolic Function in Patients With Refractory Angina Pectoris and Inducible Myocardial Ischemia on Optimal Medical Therapy. American Journal of Cardiology, 2016, 117, 1558-1561.	1.6	2

#	Article	IF	Citations
127	Effects of drug-eluting stents after rotational atherectomy. Journal of Cardiovascular Medicine, 2017, 18, 354-358.	1.5	2
128	A Novel Technique for Prosthetic Valve Retrieval After Transcatheter Aortic Valve Embolization. Canadian Journal of Cardiology, 2017, 33, 951.e1-951.e3.	1.7	2
129	Impact of Diabetes onÂClinical Outcomes After Polymer-Free Amphilimus- and Biolimus-Eluting Stent Implantation. JACC: Cardiovascular Interventions, 2019, 12, 1745-1747.	2.9	2
130	Percutaneous Repair for Secondary Mitral Regurgitation. New England Journal of Medicine, 2019, 380, 1975-1978.	27.0	2
131	Ventricular arrhythmias in patients with functional mitral regurgitation and implantable cardiac devices: implications of mitral valve repair with Mitraclip®. Annals of Translational Medicine, 2020, 8, 956-956.	1.7	2
132	Longâ€term clinical effects of recanalization of chronic coronary total occlusions in patients with left ventricular systolic dysfunction. Catheterization and Cardiovascular Interventions, 2020, 96, 831-838.	1.7	2
133	Strategies for bridge to heart transplantation: Percutaneous mitral valve repair and LVAD. Journal of Heart and Lung Transplantation, 2021, 40, 536-537.	0.6	2
134	Transcatheter therapies for secondary mitral regurgitation in advanced heart failure: what are we aiming for?. Heart Failure Reviews, 2021, , 1.	3.9	2
135	Complications of Percutaneous Coronary Intervention. , 2015, , 2297-2322.		2
136	Cardiac and sudden death after chronic total occlusion percutaneous coronary intervention: Prognostic role of the target vessel. Catheterization and Cardiovascular Interventions, 2021, 97, E789-E800.	1.7	2
137	PlaCor PRT measurement of shear-activated platelet aggregate formation in stable patients treated with single and dual antiplatelet therapy. Platelets, 2014, 25, 337-342.	2.3	1
138	Outcomes of the amphilimus-eluting polymer-free stent for chronic total occlusion treatment. Journal of Cardiovascular Medicine, 2018, 19, 564-570.	1.5	1
139	Antithrombotic therapy: less is more or the more the better?. Europace, 2020, 22, 1142-1142.	1.7	1
140	Patient selection for trans-catheter mitral valve repair versus replacement: ongoing indications and glimpse to the future. Vessel Plus, 0, 2021, .	0.4	1
141	Complications of Percutaneous Coronary Intervention., 2014,, 1-30.		1
142	Radiation Exposure and Contrast Agent Reduction During Transcatheter Aortic Valve Implantation: An Ongoing Experience. Journal of Invasive Cardiology, 2016, 28, 459-465.	0.4	1
143	Meta-Analysis of Relation Between Left Ventricular Dysfunction and Outcomes After Transcatheter Mitral Edge-to-Edge Repair. American Journal of Cardiology, 2022, 175, 88-96.	1.6	1
144	TCT-580 Outcome after percutaneous edge-to-edge mitral repair for functional and degenerative mitral regurgitation: a systematic review and meta-analysis. Journal of the American College of Cardiology, 2017, 70, B240-B241.	2.8	0

#	Article	IF	CITATIONS
145	Abnormal Angle between Interatrial Septum and Mitral Valve Plane: an Unfavorable Predictor for MitraClip Procedure. Journal of Cardiovascular Imaging, 2022, 29, 138-139.	0.7	0